Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium breve has been investigated for its potential role in supporting gut health in individuals with Celiac Disease, although the evidence is still emerging and primarily preclinical or from small clinical studies. Celiac Disease is characterized by an immune reaction to gluten, leading to inflammation and damage in the small intestine. Research indicates that people with Celiac Disease often have disrupted gut microbiota, with reduced levels of beneficial bacteria such as Bifidobacterium species. A few studies, including randomized controlled trials and in vitro experiments, suggest that supplementation with B. breve may help restore a healthier gut microbiome composition in celiac patients, particularly those on a gluten-free diet. For example, a 2015 double-blind, placebo-controlled trial by Olivares et al. showed that B. breve supplementation improved gut microbiota balance in children with Celiac Disease on a gluten-free diet. Some animal and cell culture studies have suggested that B. breve may reduce pro-inflammatory cytokine production and strengthen gut barrier function, potentially reducing the severity of gluten-induced inflammation. However, while these findings are promising, large-scale human trials are lacking, and there is insufficient evidence to recommend B. breve as a standalone treatment or established adjunct therapy for Celiac Disease. Current use is mostly as a supportive measure for gut health rather than a primary treatment for the disease itself.

More about bifidobacterium breve
More about Celiac Disease

Other ingredients used for Celiac Disease

Other health conditions supported by bifidobacterium breve

Products containing bifidobacterium breve